Agomelatine in Elderly - Finally a Patient Friendly Antidepressant In Psychogeriatry?

作者：Luzny Jan^*

来源：Actas Espanolas de Psiquiatria, 2012, 40(6): 304-307.

• Agomelatine
• MASSA antidepressant
• Major depression
• Seniors
• Montgomery-Asberg Depression Scale (MADRS)
• Clinical Global Impression scale (CGI)
• Side effects

Background: Geriatric depression is a serious psychiatric conditions with prevalence from 10-40% in community living seniors. Polymorbidity and potential vulnerability of seniors towards medication is a challenge for seeking newer, well tolerated antidepressant with good clinical efficiency and safety. Agomelatine is new promising antidepressant which could fulfill these criteria.
Objective: Evaluation of effectiveness, safety and side effects of agomelatine used for treatment senior patients with major depression hospitalized in inpatient psychogeriatric ward in Mental hospital in Kromeriz (2010-2011).
Methods: Psychiatric scales Montgomery-Asberg Depression Scale (MADRS) and Clinical Global Impression (CGI) were used initially before starting with agomelatine treatment, then after 4 and 8 weeks and finally after 12 weeks of using agomelatine. Potential side effects caused by agomelatine (side effects according AISL databasis-Automatized Information system of Registered Drugs in the Czech republic) were monitored after 12 weeks of treatment with agomelatine. Results: While treating major depression in seniors with agomelatine, decrease in Montgomery-Asberg Depression Scale (MADRS), Clinical Global Impression scale (CGI) was evident after 4 weeks of treatment and continued constantly after 8 and 12 weeks of treatment. Clinical remission was achieved in all studied patients.
Conclusion: Agomelatine proved excellent efficiency in treating severe major depression in seniors with no serious averse effects.

• 出版日期2012-12